Diaceutics PLC
("Diaceutics" or the "Company")
Transfer of Shares and Director/PDMR Shareholding
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, has today been informed that Philip White has made the following transfers of a total of 1,119,941 ordinary shares of £0.002 each in the Company ("Ordinary Shares") to his former spouse as detailed below.
On 6th April 2021, Philip White transferred 615,041 Ordinary Shares in the Company held in his own name and 504,900 Ordinary Shares in the Company held in his SIPP (the Philip White Tyres Pension Trust 81810) to Jemma White and The Xafinity SIPP re Jemma White, respectively, both for nil consideration.
As a result of this transfer, the beneficial holding of Philip White and his connected parties in the Company is 1,906,389 Ordinary Shares, representing 2.27% of the Company's issued share capital.
Enquiries:
| Diaceutics PLC | |||
| Peter Keeling, Chief Executive Officer | via Walbrook PR | ||
| Philip White, Chief Financial Officer |
| ||
|
|
| ||
| Cenkos Securities plc (Nominated adviser and broker) | +44 (0)207 397 8900 | ||
| Callum Davidson / Giles Balleny |
| ||
| Michael Johnson (Sales) |
| ||
|
|
| ||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com | ||
| Anna Dunphy | Mob: +44 (0)7876 741 001 | ||
| Paul McManus | Mob: +44 (0)7980 541 893 | ||
|
|
|
|
|
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides solutions to 36 of the world's leading pharmaceutical companies. DXRX - the Diagnostic Network ® provides unrivalled access to deep analysis and insights from the world's largest repository of diagnostic testing data on one secure platform.
About DXRX - The Diagnostic Network®
DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Philip White | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Financial Officer | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Ordinary shares of £0.002
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Transfer of ordinary shares for nil consideration to former spouse | |||||
| c. | Price(s) and volume(s) |
|
|
|
|
| |
|
| Price(s) | Volume(s) |
| ||||
|
| Nil | 1,119,941 |
| ||||
|
| |||||||
| e. | Date of the transaction | 6 April 2021 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
